Compositions comprising a heme-haloperoxidase and an amino alcohol effective for killing or inhibiting the growth of pathogenic microorganisms in the presence of a peroxide and halide and methods of use are provided.

Compositions comprising a heme-haloperoxidase and an amino alcohol effective for killing or inhibiting the growth of pathogenic microorganisms in the presence of a peroxide and halide and methods of use are provided.

Compositions for prevention and treatment of microbial infectious, such as microbial infections that comprise a biofilm, or a microbe that is capable of forming a biofilm are described. The compositions comprise an enzyme that is able to convert a substrate to release hydrogen peroxide and a substance that includes a substrate for the enzyme. The enzyme is additional to any enzyme activity able to convert the substrate to release hydrogen peroxide that may be present in the substance. The substance may be an unrefined natural substance or a substance that includes a purified substrate for the enzyme.

The present disclosure relates to novel lantibiotics, lantibiotic pharmaceutical compositions, isolated and recombinant lantibiotic-producing bacteria, bacterial pharmaceutical compositions, methods of producing novel lantibiotics from lantibiotic-producing bacteria, and methods of using such lantibiotics, lantibiotic pharmaceutical compositions, and bacterial pharmaceutical compositions to treat gram-positive bacteria infections, including vancomycin resistant enterococci infections, in patients, and to treat food and other objects to avoid gram-positive bacteria contamination.

A method of treating a cancer, the method comprising: providing a genetically modified macrophage or monocyte that contains a nucleic acid sequence encoding a Hom-1 polypeptide or a fragment thereof that contains the Hom-1 homeobox domain, wherein the nucleic acid sequence is operably linked to a heterologous promoter and the modified macrophage or monocyte expresses the Hom-1 polypeptide or the fragment thereof; and administering the modified macrophage or monocyte to a subject with a cancer.

A composition for preventing or treating hypoglycemia in a patient in need thereof has a microgel that includes crosslinked polymers containing glucose-responsive moieties; and blood glucose-raising therapeutic agent loaded on or within the microgel. The microgel further includes any one or a combination of a stabilizing component and a loading-assisting component for the blood glucose- raising therapeutic agent. The polymers containing the glucose-responsive moieties form secondary crosslinks in response to low glucose level, thereby causing shrinking of the microgel and rapid release of the blood glucose-raising therapeutic agent. The composition can be used to prepare a composite microneedle patch for preventing or treating hypoglycemia, where the composition is embedded or integrated within an array of the microneedles of the microneedle patch device.

A composition for preventing or treating hypoglycemia in a patient in need thereof has a microgel that includes crosslinked polymers containing glucose-responsive moieties; and blood glucose-raising therapeutic agent loaded on or within the microgel. The microgel further includes any one or a combination of a stabilizing component and a loading-assisting component for the blood glucose- raising therapeutic agent. The polymers containing the glucose-responsive moieties form secondary crosslinks in response to low glucose level, thereby causing shrinking of the microgel and rapid release of the blood glucose-raising therapeutic agent. The composition can be used to prepare a composite microneedle patch for preventing or treating hypoglycemia, where the composition is embedded or integrated within an array of the microneedles of the microneedle patch device.

Glucose oxidase and further compositions are described. The glucose oxidase compositions have glucose oxidase and at least one ingredient selected from one or more of carbohydrate (e.g. dietary fibre or saccharide), polyol or sugar alcohol while further compositions are sweeteners, food, compositions for fortification of food, nutraceuticals and pharmaceuticals. The compositions incorporate low glycemic index nutritive compound of glycemic index less than 70, preferably less than 50, and are in the form of powders, granules, crystalline compositions, flours, pills, tablets, capsules, pellets, powder for oral suspensions, gels, liquid solutions and suspensions, and sterile preparations. The compositions regulate one or more diseases/conditions, including but not limited to those associated with blood, kidney, thyroid, nerves, joints, weight, diabetes, oxidative stress, cardiovascular disease, insulin resistance, amyloid foot ulcers, cataract, glaucoma, hypertension, metabolic disorders, digestive disorders, polycystic ovarian syndrome, mastopathy, dupuytren's contracture, gingivitis, periodontitis, dental caries, mouth disorders, cognitive dysfunction, and Parkinson's disease.

The present disclosure relates to a hypoxia-inducing cryogel, comprising one or more polymer and one or more hypoxia-inducing agent. The present disclosure additionally relates to a hypoxia-inducing construct, comprising a cryogel and a support. Methods of reducing concentration of oxygen in a medium, comprising contacting the medium with a hypoxia-inducing cryogel (HIC) or a hypoxia-inducing construct are disclosed. Additionally, methods of inducing hypoxia in a cell, comprising contacting the cell with a medium, wherein the medium comprises a HIC or a hypoxia-inducing construct are disclosed.

A composition comprising an amphiphilic polymeric material that is both hydrogen peroxide- and hypoxia-sensitive is described. The composition can further include a glucose-oxidizing enzyme and insulin, a bioactive derivative thereof, and/or another therapeutic agent (e.g., another diabetes treatment agent). The polymeric material can form vesicles that comprise single or multiple layers of the polymeric material that enclose the glucose-oxidizing enzyme and the insulin, bioactive derivative and/or other therapeutic agent. The vesicles can be loaded into microneedles to, for example, prepare microneedle arrays for skin patches. Methods of delivering insulin to a subject using the compositions, vesicles, microneedles, and/or microneedle array skin patches are also described.